

Corvus Pharmaceuticals, Inc.  
Form 8-K  
April 26, 2018

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**  
**Date of Report (Date of earliest event reported): April 26, 2018**

---

**CORVUS PHARMACEUTICALS, INC.**  
**(Exact name of registrant as specified in its charter)**

---

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-37719**  
**(Commission**  
**File Number)**

**46-4670809**  
**(IRS Employer**  
**Identification Number)**

**863 Mitten Road, Suite 102**  
**Burlingame, CA 94010**  
**(Address of principal executive offices, including Zip**  
**Code)**

**Registrant's telephone number, including area code: (650) 900-4520**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ]
- [  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ]
- [  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ]
- [  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- ]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]

---

**Item 8.01. Other Events.**

On April 26, 2018, Corvus Pharmaceuticals, Inc. issued a press release announcing initiation of its Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	<u>Press release titled, "Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer" dated April 26, 2018.</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORVUS PHARMACEUTICALS, INC.**

Date: April 26, 2018

By: /s/ Leiv Lea  
Leiv Lea  
Chief Financial Officer